Moberg Pharma Annual Report 2013

Regulatory News:

Moberg Pharma (STO:MOB)

Moberg Pharma Annual Report 2013

Dear Shareholders,

2013 was an eventful year with notable successes, as well as some setbacks. Sales to our distributors were weaker than anticipated and, at the beginning of the year, we discontinued the Limtop project. At the same time, our U.S. operation developed successfully with organic growth of 31 percent. Kerasal Nail™ doubled its market share to nearly 20 percent and is now the market-leading product in its segment in the U.S. In 2013, we also continued to launch new products based on internal product development. The year closed positively, with the acquisition of a portfolio of OTC drugs for the U.S. market, and highly encouraging interim results for MOB-015, our main product under development.

Report available at: http://mb.cision.com/Main/1662/9567973/232542.pdf

This information was brought to you by Cision http://news.cision.com